Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

Abstract Introduction Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledi...

Full description

Bibliographic Details
Main Authors: Cristina Aurora São Pedro Soeiro, Celina Andreia Melo Gonçalves, Marta Sofia Correia Marques, Maria Josefina Vazquez Méndez, Ana Paula Ribeiro Almeida Tavares, Ana Maria Lacerda Morgado Fernandes de Carvalho de Aboim Horta, Rui Manuel do Rosário Sarmento-Castro
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Infectious Diseases
Subjects:
Co-infection HIV/HCV
HCV treatment
Sofosbuvir/ledipasvir
Renal toxicity
Tenofovir
Protease inhibitor
Online Access:http://link.springer.com/article/10.1186/s12879-018-3278-3

Internet

http://link.springer.com/article/10.1186/s12879-018-3278-3

Similar Items